布地与泼尼松治疗活动性病比较.pdfVIP

GASTROENTEROLOGY 1998;115:835–840 Budesonide Versus Prednisone in the Treatment of Active Crohn’s Disease SIMON BAR–MEIR,* YEHUDA CHOWERS,* ALEXANDRA LAVY,‡ DOV ABRAMOVITCH,§ ¶ # AMOS STERNBERG, GEORGES LEICHTMANN, RON RESHEF, SHMUEL ODES,** ‡‡ §§ ¶¶ MENACHEM MOSHKOVITZ, RAPHAEL BRUCK, RAMI ELIAKIM, ERAN MAOZ, ## ULRI ITTMANN, and the ISRAELI BUDESONIDE STUDY GROUP Department of Gastroenterology *Chaim Sheba Medical Center, Hashomer; ‡Rambam, Haifa; §Assaf Harofeh, Medical Center, Zerifin; Hillel Yafe Medical Center, Hadera; ¶ Meir General Hospital, Kfar Saba; #Naharia Medical Center, Naharia; **Soroka Medical Center, Beersheva; ‡‡Ichilov, Aviv; §§Edith Wol Medical Center, Holon; Hadassah Mount Scopes Medical Center, Jerusalem; and ##Rabin Medical Centers, Israel; and ***Dr Falk, Pharma Gmb H, Freiburg, Germany Background Aims: Budesonide (BUD) is a potent Budesonide (BUD) is a synthetic steroid with high steroid that undergoe tensive first-pass metabo- affinity for the steroid receptor. Af bsorption, the lism. BUD orporated in a pH-dependent formulation drug is metabolized in the liver and 90% is converted has been proposed as ternative treatment for into metabolites with low glucocorticoid activity.4,5 Crohn’s disease (CD). The aim of this study was to Because of these characteristics, BUD can potentially compare the efficacy an